Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized BX004-A for chronic Pseudomonas aeruginosa pulmonary infection in adults with cystic fibrosis
NL-OMON53309Phase 2Active, not recruiting
- Sponsor
- BiomX
- Start
- Jun 2023
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Pseudomonas aeruginosa pulmonary infection and cystic fibrosis (CF) comparing BX004-A high dose + usual inhaled antibiotics with Placebo + usual inhaled antibiotics (2 arms). Primary endpoint: Safety and tolerability of nebulized BX004-A. Started Jun 2023; status: active, not recruiting.
02
Drugs
BX004
03
Conditions
Pseudomonas aeruginosa pulmonary infectioncystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON53309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53309.